0001209191-22-048342.txt : 20220901
0001209191-22-048342.hdr.sgml : 20220901
20220901181900
ACCESSION NUMBER: 0001209191-22-048342
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20220901
FILED AS OF DATE: 20220901
DATE AS OF CHANGE: 20220901
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cline Christopher R.
CENTRAL INDEX KEY: 0001943192
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36257
FILM NUMBER: 221222662
MAIL ADDRESS:
STREET 1: C/O TRAVERE THERAPEUTICS, INC.
STREET 2: 3611 VALLEY CENTRE DRIVE, STE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Travere Therapeutics, Inc.
CENTRAL INDEX KEY: 0001438533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262383102
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 888-969-7879
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Retrophin, Inc.
DATE OF NAME CHANGE: 20130220
FORMER COMPANY:
FORMER CONFORMED NAME: Desert Gateway, Inc.
DATE OF NAME CHANGE: 20080625
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2022-09-01
0
0001438533
Travere Therapeutics, Inc.
TVTX
0001943192
Cline Christopher R.
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DRIVE, STE 300
SAN DIEGO
CA
92130
0
1
0
0
Chief Financial Officer
Common Stock
28723
D
Employee Stock Option (Right to Buy)
12.51
2024-08-10
Common Stock
40000
D
Employee Stock Option (Right to Buy)
32.49
2025-06-30
Common Stock
15000
D
Employee Stock Option (Right to Buy)
16.23
2026-05-18
Common Stock
20000
D
Employee Stock Option (Right to Buy)
17.44
2027-05-16
Common Stock
20000
D
Employee Stock Option (Right to Buy)
25.25
2028-05-09
Common Stock
12500
D
Employee Stock Option (Right to Buy)
17.96
2029-05-08
Common Stock
10000
D
Employee Stock Option (Right to Buy)
15.46
2030-01-30
Common Stock
12500
D
Employee Stock Option (Right to Buy)
26.88
2031-01-20
Common Stock
16250
D
Employee Stock Option (Right to Buy)
27.50
2032-01-30
Common Stock
17500
D
Employee Stock Option (Right to Buy)
28.55
2032-04-09
Common Stock
5000
D
The stock option is fully vested and exercisable.
One-fourth of the shares subject to the stock option vested and become exercisable on May 9, 2020, and the remaining shares vest in 36 equal monthly installments thereafter.
One-fourth of the shares subject to the stock option vested and become exercisable on January 31, 2021, and the remaining shares vest in 36 equal monthly installments thereafter.
One-fourth of the shares subject to the stock option vested and became exercisable on January 21, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.
One-fourth of the shares subject to the stock option will vest and become exercisable on January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.
One-fourth of the shares subject to the stock option will vest and become exercisable on April 10, 2023, and the remaining shares vest in 36 equal monthly installments thereafter.
/s/ Elizabeth E. Reed, Attorney-in-Fact
2022-09-01
EX-24
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
Know all, by these presents, that the undersigned hereby constitutes and
appoints each of Elizabeth E. Reed and Sandra Calvin, signing individually, the
undersigned's true and lawful attorneys-in fact and agents to:
(1) execute for and on behalf of the undersigned, an officer, director or holder
of 10% of more of a registered class of securities of Travere Therapeutics, Inc.
(the "Company"), Forms 3, 4 and 5 in accordance with Section 16(a) of the
Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules
thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute such Form 3, 4 or 5,
complete and execute any amendment or amendments thereto, and timely file such
forms or amendments with the United States Securities and Exchange Commission
and any stock exchange or similar authority; and
(3) take any other action of any nature whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.
This Power of Attorney shall remain in full force and effect until the earliest
to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5
with respect to the undersigned's holdings of and transactions in securities
issued by the Company, (b) revocation by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact
individually, until such attorney-in-fact shall no longer be employed by the
Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 11th day of August, 2022.
/s/ Christopher R. Cline